.Your mission The Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer research center dedicated to conducting research and driving innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukemia and other hematologic malignancies, with the final aim of finding a cure for these diseases.It was created in 2010, and since then has experienced an exponential growth.
The IJC is also part of the network of Excellence Research Centers of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024.
Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC).
Additionally, IJC is one of the centers integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII).The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services.
The IJC has six locations integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Trueta, Hospital del Mar, and Hospital San Joan de Déu.
This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.We are looking to fill in a BIOINFORMATICS POSTDOCTORAL POSITION in Blood Stem Cell Identity group, led by Dr. Vincenzo Calvanese.RESEARCH DESCRIPTION:Hematopoietic stem cells (HSC) are a life-saving therapy for leukemia and have broadened applications to gene and cell therapy against other cancers, genetic, autoimmune, and infectious diseases.
Yet, practical limitations, such as donor-matching or insufficient cell number render these therapies unfeasible or unsuccessful for many patients.
Attempts to overcome these limitations have been unable to create a reliable source of HSC for patients: while we can generate human HSC from pluripotent stem cells, they resemble early development stages, lacking many of the functional maturation hallmarks.The Postdoctoral Researcher will join a team to work on a project to identify transcriptional regulation mechanisms that sustain HSC self-renewal, and their relevance for the establishment and maintenance of the leukemia stem cell population in the context of blood cancer.
To dissect the nature and function of these cells, we use a combination of epigenomics and transcriptomics, on cell lines and human primary tissues, combining in vitro and in vivo models of human normal and leukemic development